Plasticell, a developer of cell therapies, has partnered with Kings College London to progress preclinical trials of its artificial blood platelet product, manufactured from pluripotent stem cells.    Plasticell has developed methods of producing functional platelets from human induced pluripotent stem cells (iPSCs) and has scaled these up to intermediate bioreactor level, allowing manufacture of product for preclinical studies. Kings College will contribute expertise and in vivo models to cha...